Trials / Completed
CompletedNCT02170311
Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia
"Phase Ib Study of Z-213 in Subjects With Iron-deficiency Anemia - To Investigate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics -"
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Zeria Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The safety, tolerability, pharmacokinetics and pharmacodynamics of Z-213 will be investigated in patients with iron-deficiency anemia after administration of a single dose (100 mg, 500 mg, 800 mg or 1,000 mg iron).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Z-213 |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-02-01
- Completion
- 2015-03-01
- First posted
- 2014-06-23
- Last updated
- 2015-03-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02170311. Inclusion in this directory is not an endorsement.